Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.

AJ Mast | Bloomberg | Getty Images

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.)

Read More: World News | Entertainment News | Celeb News
CNBC

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

War, what war? Putin looks to woo new business partners willing to overlook its invasion of Ukraine

Russian President Vladimir Putin is seen while visiting the Lakhta Center on…

China and Hong Kong stocks lost nearly $5 trillion in 3 years — more than India’s market cap

MUMBAI, MAHARASHTRA, INDIA – 2024/02/01: A circular metal emblem with words ‘This…

AI startup Stability lays off 10% of staff after controversial CEO’s exit: Read the full memo

Emad Mostaque, founder and CEO of Stability AI, speaks during the Bloomberg…

Oil tanker hit by missile after transiting Red Sea — Houthis claim responsibility

Children walk near a billboard bearing the image of targeting ships, on…